KY-556 is a promising and orally-active pro-drug of disodium cromoglycate (DSCG). It also against allergic diseases.

N-556 (100 mg/kg, p.o.) displays the prolongation of survival time in the rat systemic anaphylaxis. N-556 (100 mg/kg, p.o.) significantly inhibits the increased airway resistance in experimental asthma in rats. N-556 (10-100 mg/kg, p.o.) inhibits dose-dependently the 48-hr homologous passive cutaneous anaphylaxis (PCA) in rats, and the duration of action is longer than that of intravenous Disodium cromoglycate (DSCG). The oral anti-allergic effect of KY-556 is investigated. N-556 (20 and 100 mg/kg once a day for 20 consecutive days, p.o.) tends to inhibit the histamine release from actively sensitized rat lung fragments [1].

110816-78-9

C33H37ClN2O12

689.11

N556;KY-556

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years